Olema Pharmaceuticals Q1 FY24: net loss $31.0M; diluted EPS −$0.56
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0000950170-24-055686
- Document
- 10-Q
- Exhibit 10.1
- Material contract
Key figures from this report
These are the numbers Olema Pharmaceuticals reported for Q1 FY24, the quarter ended Mar 31, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Net income−$31.0MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Diluted EPS−$0.56No year-earlier figure tagged10-Q income statement, on EDGAR
- Cash and cash equivalents$33.7MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
- Cash from operations−$23.5MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Annexon ANNX public float $244M, Jun 30, 2025
- DBV Technologies DBVT public float $251M, Jun 30, 2025
- Heron Therapeutics HRTX public float $235M, Jun 30, 2025
- Corvus Pharmaceuticals CRVS public float $252M, Jun 30, 2025
- Verastem VSTM public float $254M, Jun 30, 2025